Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy

Outcome of patients with primary refractory acute myeloid leukemia remains unsatisfactory. We conducted a prospective phase II clinical trial with gemtuzumab ozogamicin (3 mg/m2 intravenously on day 1), all-trans retinoic acid (45 mg/m2 orally on days 4–6 and 15 mg/m2 orally on days 7–28), high-dose...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Marie-Luise Hütter-Krönke, Axel Benner, Konstanze Döhner, Jürgen Krauter, Daniela Weber, Margit Moessner, Claus-Henning Köhne, Heinz A. Horst, Ingo G.H. Schmidt-Wolf, Mathias Rummel, Katharina Götze, Elisabeth Koller, Andreas L. Petzer, Hans Salwender, Walter Fiedler, Heinz Kirchen, Detlef Haase, Stephan Kremers, Matthias Theobald, Axel C. Matzdorff, Arnold Ganser, Hartmut Döhner, Richard F. Schlenk
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Ferrata Storti Foundation 2016-07-01
سلاسل:	Haematologica
الوصول للمادة أونلاين:	https://haematologica.org/article/view/7770
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!